These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 6375701)

  • 1. Apoproteins: determinants of lipoprotein metabolism and indices of coronary risk.
    Thompson G
    Br Heart J; 1984 Jun; 51(6):585-8. PubMed ID: 6375701
    [No Abstract]   [Full Text] [Related]  

  • 2. Monogenic dyslipidemias: window on determinants of plasma lipoprotein metabolism.
    Hegele RA
    Am J Hum Genet; 2001 Dec; 69(6):1161-77. PubMed ID: 11704922
    [No Abstract]   [Full Text] [Related]  

  • 3. Apolipoprotein E (role in lipoprotein metabolism and pathophysiology of hyperlipoproteinemia type III).
    Utermann G
    Ric Clin Lab; 1982; 12(1):23-30. PubMed ID: 6283616
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of antihypertensive drugs on plasma lipids.
    Nakamura H
    Am J Cardiol; 1987 Sep; 60(9):24E-28E. PubMed ID: 3661454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Apolipoproteins - an important diagnostic indicator in the evaluation of coronary disease risk].
    Naruszewicz M; Nowicka G
    Pol Arch Med Wewn; 1980 Aug; 64(2):161-6. PubMed ID: 7433154
    [No Abstract]   [Full Text] [Related]  

  • 6. [Relation of serum lipids disorders and ischemic heart disease in diabetics].
    Muto E
    Hokkaido Igaku Zasshi; 1989 Jul; 64(4):406-10. PubMed ID: 2583664
    [No Abstract]   [Full Text] [Related]  

  • 7. [Apolipoproteins A-1 and B of the blood plasma and apolipoproteins A-1 of 2 high-density lipoprotein subclasses in ischemic heart disease patients with various lipoprotein spectra].
    Metel'skaia VA; Perova NV; Chernysheva NP; Kurdanov KhA; Polesskiĭ VA
    Biull Vsesoiuznogo Kardiol Nauchn Tsentra AMN SSSR; 1983; 6(1):83-9. PubMed ID: 6407489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of CS-514, a new inhibitor of HMG CoA reductase, on plasma lipids, lipoproteins and apoproteins in patients with primary hypercholesterolemia.
    Kazumi T; Yoshino G; Kasama T; Iwatani I; Iwai M; Morita S; Baba S
    Horm Metab Res; 1986 Sep; 18(9):654-5. PubMed ID: 3096862
    [No Abstract]   [Full Text] [Related]  

  • 9. Genetics of coronary heart disease and its risk factors.
    Berg K
    Prog Clin Biol Res; 1985; 177():351-74. PubMed ID: 3160046
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of pirozadil on lipids, lipoproteins and apolipoproteins in Japanese with type IIa hyperlipoproteinemia.
    Shinomiya M; Ishikawa Y; Shirai K; Saito Y; Yoshida S
    Arzneimittelforschung; 1987 Sep; 37(9):1069-71. PubMed ID: 3435604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia.
    Seed M; Hoppichler F; Reaveley D; McCarthy S; Thompson GR; Boerwinkle E; Utermann G
    N Engl J Med; 1990 May; 322(21):1494-9. PubMed ID: 2139920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein (a) and coronary heart disease in patients with familial hypercholesterolemia.
    N Engl J Med; 1990 Dec; 323(25):1773-4. PubMed ID: 2147230
    [No Abstract]   [Full Text] [Related]  

  • 13. Lipoprotein metabolism and the role of apolipoproteins as metabolic programmers.
    Dolphin PJ
    Can J Biochem Cell Biol; 1985 Aug; 63(8):850-69. PubMed ID: 3904949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of the combined administration of guar-bezafibrate on lipid, apolipoprotein and lipoprotein in patients with primary hyperlipoproteinemia type II].
    Wirth A; Schlierf G; Middelhoff G; Arntz HR; Hansen W; Vollmar J; Bräuning C
    Beitr Infusionther Klin Ernahr; 1983; 12():99-108. PubMed ID: 6316922
    [No Abstract]   [Full Text] [Related]  

  • 15. [Remnant hyperlipidemia].
    Tada N
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():112-8. PubMed ID: 11347041
    [No Abstract]   [Full Text] [Related]  

  • 16. [Lipoproteins in plasma and fats in nutrition in the pathogenesis of coronary heart disease. Remarks on the causes and limits of the lipid theory].
    Zöllner N; Keller C
    Internist (Berl); 1984 May; 25(5):261-7. PubMed ID: 6376406
    [No Abstract]   [Full Text] [Related]  

  • 17. [Lipoprotein spectrum and makeup of the individual classes in coronary arteriosclerosis with a varying lipid level in the blood plasma].
    Gasilin VS; Kurdanov KhA; Perova NV; Torkhovskaia TI; Gadzhalova SI
    Kardiologiia; 1980 May; 20(5):42-6. PubMed ID: 7392382
    [No Abstract]   [Full Text] [Related]  

  • 18. Laboratory-based assessment of plasma lipids and lipoproteins for the classification of familial hypercholesterolemic and hypertriglyceridemic states.
    Demacker PN
    Semin Vasc Med; 2004 Feb; 4(1):13-22. PubMed ID: 15199429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipoproteins and coronary heart disease.
    Betteridge DJ
    J Hum Hypertens; 1989 Dec; 3 Suppl 2():13-24; discussion 24-5. PubMed ID: 2691691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Advances on the relation between the metabolism and lipids and coronary diseases].
    Zhu ML; Sun YT
    Zhonghua Xin Xue Guan Bing Za Zhi; 1985 Sep; 13(3):225-7. PubMed ID: 3912149
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.